GlassScriptPhysician profile
Su K Lee
NPI 1871510370
$22,574.94
in general payments reported to CMS, 2019-2025
42 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,958 · 2020: $1,638 · 2021: $2,864 · 2022: $3,971 · 2023: $5,749 · 2024: $2,271 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,127 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Education: $17.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,126.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Education | $17.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,314.15 | 2019-2025 | |
| Amgen INC. | $2,237.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,142.83 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $1,570.58 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $719.20 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $610.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.14 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $539.54 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $533.69 | 2021-2025 | |
| Allergan, INC. | $472.75 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $383.08 | 2019-2025 | Cobenfy, Eliquis |
| Janssen Pharmaceuticals, INC | $339.65 | 2019-2022 | |
| Ardelyx, INC. | $262.37 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $247.05 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Almatica Pharma LLC | $230.05 | 2023-2025 | Loreev Xr, Gralise |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.